Capsulomics
Halethorpe, US · Maryland corporation · 6 known investors
Find your way into Capsulomics
Sign up to see every warm intro you have to Capsulomics
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Capsulomics team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Capsulomics offers Esopredict, a DNA methylation-based risk-stratification test that predicts progression from Barrett's esophagus to high-grade dysplasia or esophageal adenocarcinoma for gastroenterologists and pathologists. The test is used as a secondary option when the company's primary TissueCypher spatialomics test cannot provide results.
Founders & leadership

Board
Investors · 6
How we know: Early Light Ventures's portfolio page · the VCSheet dataset · Not right? Tell us
How we know: biospace.com · gaingels.com · Not right? Tell us
How we know: Maryland TEDCO's portfolio page · Not right? Tell us
How we know: biospace.com · Not right? Tell us
Also in the syndicate · 1
Funding
SEC filings, press & company announcements$2.4M disclosed across 1 of 3 rounds · 2019–2023
- Undisclosed amountseed roundMar 2023
Gaingels, Riptide Ventures, TEDCO, Wexford Science and Technology
Source ↗ - Undisclosed amountseed roundMar 2022Source ↗
▶$2.4MraisedMar 2025 · 10 investors · BiotechnologyRule 506(b)
- John NeiderhuberDirector
- Daniel LunzExecutive Officer, Director
- William StevensExecutive Officer
- Stephen MeltzerDirector
- Offering amount
- $3M
- Amount sold
- $2.4M
- First sale
- Dec 2019
- Incorporated
- Corporation, Maryland
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
In the news
Frequently asked questions
- What does Capsulomics do?
- Capsulomics offers Esopredict, a DNA methylation-based risk-stratification test that predicts progression from Barrett's esophagus to high-grade dysplasia or esophageal adenocarcinoma for gastroenterologists and pathologists. The test is used as a secondary option when the company's primary TissueCypher spatialomics test cannot provide results.
- Who are Capsulomics's investors?
- Capsulomics's investors include Early Light Ventures, Gaingels, Maryland TEDCO, TEDCO, Riptide Ventures.
- How much funding has Capsulomics raised?
- Capsulomics has disclosed $2.4M raised across 1 of its 3 known rounds.
- Where is Capsulomics headquartered?
- Capsulomics is headquartered in Halethorpe, US.


__Twitter.png)
